688247 Stock Overview
Sinotherapeutics Inc., a specialty pharmaceutical company, develops generic and formulation products in China.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Sinotherapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥9.00 |
| 52 Week High | CN¥16.67 |
| 52 Week Low | CN¥6.30 |
| Beta | 0 |
| 1 Month Change | 7.66% |
| 3 Month Change | -0.88% |
| 1 Year Change | -44.89% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -33.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688247 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 10.0% | 4.5% | 2.2% |
| 1Y | -44.9% | -13.4% | -14.2% |
Return vs Industry: 688247 underperformed the CN Pharmaceuticals industry which returned -13.4% over the past year.
Return vs Market: 688247 underperformed the CN Market which returned -14.2% over the past year.
Price Volatility
| 688247 volatility | |
|---|---|
| 688247 Average Weekly Movement | 9.5% |
| Pharmaceuticals Industry Average Movement | 7.6% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 688247 has not had significant price volatility in the past 3 months.
Volatility Over Time: 688247's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 248 | n/a | www.sinotherapeutics.com |
Sinotherapeutics Inc., a specialty pharmaceutical company, develops generic and formulation products in China. It offers posaconazole delayed-release tablets, ursodeoxycholic acid capsules, bupropion hydrochloride extended-release tablets, paroxetine extended-release tablets, sevelamer carbonate tablets, and propafenone hydrochloride extended-release capsules. The company provides CRO/CDMO services including pre-formulation study, formulation and process development, clinical sample manufacturing, NDA registration batch manufacturing, quality standard establishment, and regulatory dossier document preparation and submission.
Sinotherapeutics Inc. Fundamentals Summary
| 688247 fundamental statistics | |
|---|---|
| Market cap | CN¥4.08b |
| Earnings (TTM) | CN¥60.54m |
| Revenue (TTM) | CN¥298.78m |
67.4x
P/E Ratio13.7x
P/S RatioIs 688247 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688247 income statement (TTM) | |
|---|---|
| Revenue | CN¥298.78m |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥298.78m |
| Other Expenses | CN¥238.24m |
| Earnings | CN¥60.54m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | 0.13 |
| Gross Margin | 100.00% |
| Net Profit Margin | 20.26% |
| Debt/Equity Ratio | 0.008% |
How did 688247 perform over the long term?
See historical performance and comparison